EGFR and neoplasm: Western blot analysis on tumor samples from mice sacrificed on day 14, after 1 week of treatment, demonstrated that saracatinib reduces EGFR phosphorylation similar to that observed with erlotinib, whereas dasatinib failed to do so (Figure 2E).